There is evidence for increased JAK/STAT signaling in a subset of T-ALL [35, 36], with in vitro studies showing activity of JAK2 inhibitors alone or in combination with dexamethasone [37] or MDM2i [38] in JAK3-mutated T-ALL. This evidence concerns the gene JAK3 and acute lymphoblastic leukemia.